Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

BIC is an integrase strand transfer inhibitor that has a higher barrier to resistance and is only used in combination. LEN has been approved as a method of pre-exposure prophylaxis but has also been ...

Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...

Approved in the US as the world’s first twice-yearly HIV prevention shot, lenacapavir is now set to be made in India at a ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

Diabetes is not a lifestyle issue, it is a justice issue, and slow death is still a death. As insulin prices soar and test strips vanish from public clinics, South Africans are dying of inequality. A ...

Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...

Around 54 000 people died of TB in South Africa in 2024 and 249 000 fell ill with the disease, according to new estimates ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...

The Global Tuberculosis Report 2025 states that India, despite seeing a drastic drop in incidence rates since 2010, still ...

The University of Houston is part of a $21.2 million Texas effort to tackle the opioid epidemic by examining opioid ...